Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | JUN | P05412 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15732934 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2JUNNFKB1 | |
| SCHEMBL9515132 | 0.76 | ALDH1A1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL30071868 | 0.71 | ALDH1A1 (0.42) | KDM4EALDH1A1SMN1; SMN2EGFRCSNK1A1 | |
| SCHEMBL9798129 | 0.69 | PDXK (0.32) | — | |
| SCHEMBL1233375 | 0.68 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2EGFRRPS6KA5 | |
| SCHEMBL30518204 | 0.68 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2EGFRRPS6KA5 | |
| SCHEMBL21128373 | 0.68 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4 | |
| SCHEMBL20953550 | 0.68 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5522255 | 0.68 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4 | |
| SCHEMBL1188746 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334295-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuoscience, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117597333-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 维吉尔神经科学股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-115867284-A | Heterocyclic compounds as trigger receptor 2 agonists expressed on myeloid cells and methods of use | 安进公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022236272-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |